A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2016
At a glance
- Drugs AGN 223575 (Primary)
- Indications Eye disorders
- Focus Pharmacokinetics
- Sponsors Allergan
- 11 Apr 2016 Number of arms changed from 5 to 7 as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov record.